MMV recognizes the power of partnerships and that its vision of a malaria-free world can only be achieved through collaboration with diverse organizations. From R&D, through making new medicines accessible, to supporting global consortia, MMV prides itself on its collaboration with the following groups:
MMV’s work would not be possible without our donors. We receive funding and support from government agencies, private foundations, international organizations, corporations, corporate foundations and private individuals. These funds are used to finance the MMV portfolio of R&D projects and to support specific, targeted access interventions that make it easier for vulnerable populations to access MMV products.
Private sector (Biotech & Pharma)
MMV leverages the facilities, knowledge and expertise of the pharmaceutical and biotechnology industries, drawing on their valuable experience and resources at every stage of the drug development process and applying it to our own. These could include gaining access to novel and proprietary compound libraries to boost the diversity of our candidate drugs in discovery research or benefiting from industry experience in manufacturing and distribution in preparation for the launch of one of our products.
Similar to our collaboration principles with academia, where MMV is funding a research programme we expect the partner, at a minimum, to match the value of the contract through in-kind contributions (for example staff costs, laboratory space, equipment, overheads), thus maximizing MMV’s financial resources.
Our partnerships with the public sector span a large number of different organizations and functions that can be grouped into three entities:
Research & academic institutions
MMV’s partnerships with research and academic institutions bring together world class science and creativity. As the primary function of academic institutions is to generate and share knowledge not driven by profit, they are well positioned to carry out specialized research during the discovery phase of the R&D process. Similar to our collaboration principles with the private sector, MMV also negotiates in-kind contributions from academic partners to maximize MMV’s funds.
MMV interacts with many governments, a number of which are donors keen to support global health initiatives. Our work would not be possible without these key partnerships. In addition, MMV works closely with other governments in malaria-endemic countries via their Ministries of Health, assisting and advising on malaria treatment and control strategies. These high-level partnerships form an integral part of our Access work and have allowed us to implement innovative approaches to expand access to treatment through public, private and community-health sectors. As such, these partnerships are critical to the implementation of MMV projects in malaria-endemic countries.
In addition to working with the public and private sectors, MMV also interacts with a large number of international organizations in a two-way dialogue to shape the malaria agenda and implement policy. This is mutually beneficial. International organizations are informed of MMV’s advances in antimalarial drug development and we are informed in advance of imminent policy developments.
NGOs and non profit organizations
Non-governmental organizations (NGOs) and non profit organizations occupy a special niche in our partnership network often providing skills and knowledge that bridge the private and public sector or government partnerships.This group of organizations includes fellow product development partnerships as well as advocacy initiatives seeking to raise awareness about the need for new malaria medicines.
Clinical trials are a key phase in the R&D process and determine if a new drug is effective and well tolerated by patients. Over the past 10 years MMV has built up a significant network of clinical trial sites in malaria-endemic countries. Projects at these sites helped build up research capacity and stimulate critical research. While building research capacity in endemic countries is not one of our primary objectives (between 2005 and 2008, only 2% of the total R&D expenses were invested in capacity building), it is a natural outcome of our R&D work. We provide training in good clinical practice and help to ensure that that trial sites meet stringent regulatory requirements. Researchers and scientists in endemic countries are a rich resource and MMV is proud to have been able to contribute to their research environment and continued training.